ALS Center, IRCCS Istituto Auxologico Italiano

University of Milan Medical School

The ALS Centre is a referral institution in Italy for the diagnosis and care of patients affected by ALS and other motor neuron diseases, offering a multidisciplinary team, clinical trials, genetic diagnosis and biomarker investigations.

MilanMedicalSchool_Logo
University of Milan Medical School

We offer adequate clinical diagnosis with the support of a multidisciplinary team and a centre for clinical trials. Research in the Laboratory of Neuroscience mainly focuses on genetics of ALS, ALS disease mechanisms using in vitro cell models, iPSCs as a bioassay of clinical relevance, and biomarker identification. We have made a big effort to develop eye tracking and BCI technologies for the definition of neuropsychological changes in people with ALS. The Milan ALS Centre has been audited by FDA in 1997 for a clinical trial.

Contact
Location
International Medical School, University of Milan, Milan, Metropolitan City of Milan, Italy

Our Specialists

Vincenzo Silani

Professor of Neurology and Chairman

Vincenzo Silani is Professor of Neurology, Director of the Department of Neurology-Stroke […]

Vincenzo Silani
Current trials
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Read more
Active
Phase iii

ALXN1210-ALS-308 trial

Industry trial
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Read more
Active
Phase iii

VALOR study

Industry trial
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more